AU2003209265A1 - Mrp9 and its use detecting and treating cancer - Google Patents
Mrp9 and its use detecting and treating cancerInfo
- Publication number
- AU2003209265A1 AU2003209265A1 AU2003209265A AU2003209265A AU2003209265A1 AU 2003209265 A1 AU2003209265 A1 AU 2003209265A1 AU 2003209265 A AU2003209265 A AU 2003209265A AU 2003209265 A AU2003209265 A AU 2003209265A AU 2003209265 A1 AU2003209265 A1 AU 2003209265A1
- Authority
- AU
- Australia
- Prior art keywords
- mrp9
- treating cancer
- use detecting
- detecting
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 101150067199 abcC12 gene Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35005302P | 2002-01-17 | 2002-01-17 | |
| US60/350,053 | 2002-01-17 | ||
| US37512102P | 2002-04-22 | 2002-04-22 | |
| US60/375,121 | 2002-04-22 | ||
| PCT/US2003/001340 WO2003062446A2 (en) | 2002-01-17 | 2003-01-15 | Mrp9 and its use detecting and treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003209265A1 true AU2003209265A1 (en) | 2003-09-02 |
| AU2003209265A8 AU2003209265A8 (en) | 2005-11-17 |
Family
ID=27616760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003209265A Abandoned AU2003209265A1 (en) | 2002-01-17 | 2003-01-15 | Mrp9 and its use detecting and treating cancer |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003209265A1 (en) |
| WO (1) | WO2003062446A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114437209B (en) * | 2022-01-25 | 2022-09-20 | 北京弘进久安生物科技有限公司 | Monoclonal antibody specifically binding to abrin and application thereof |
| CN115772219B (en) * | 2022-07-29 | 2023-11-14 | 生工生物工程(上海)股份有限公司 | Binding protein capable of specifically binding MRP1 protein, kit and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001057214A2 (en) * | 2000-02-03 | 2001-08-09 | Lexicon Genetics Incorporated | Human transporter proteins and polynucleotides encoding the same |
-
2003
- 2003-01-15 AU AU2003209265A patent/AU2003209265A1/en not_active Abandoned
- 2003-01-15 WO PCT/US2003/001340 patent/WO2003062446A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003209265A8 (en) | 2005-11-17 |
| WO2003062446A9 (en) | 2004-03-04 |
| WO2003062446A2 (en) | 2003-07-31 |
| WO2003062446A3 (en) | 2005-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003232485A1 (en) | Neopeptides and methods useful for detection and treatment of cancer | |
| AU2003213144A1 (en) | Alkylating agent combinations in the treatment of cancer | |
| AU2003237367A1 (en) | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer | |
| AU2003293376A1 (en) | Anti-angiogenic compounds and their use in cancer treatment | |
| AU2003240959A1 (en) | Microarray detector and methods | |
| AU2003212634A1 (en) | Compounds useful in the treatment of cancer | |
| AU2002319338A1 (en) | Cancer specific oligosaccharide sequences and use thereof | |
| AU2002352007A1 (en) | Agents and methods for detecting human adenoviruses | |
| AU2003299943A1 (en) | Heterocycles and uses thereof | |
| AU2003251766A1 (en) | Partially ester-exchanged sipm and process therewith | |
| GB0201498D0 (en) | Materials and methods for treating cancer | |
| AU2003293013A1 (en) | Diagnosing and treating hematopoietic cancers | |
| AU2003283339A1 (en) | Cancer therapy determination | |
| AU2003231803A1 (en) | Treatment of cancer with mefloquire | |
| AU2002366195A1 (en) | Use of bisindolmaleimide and gemcitabine for the treatment of cancer | |
| AU2003302173A1 (en) | Spirotetrathiocarbamates and spirooxothiocarbamates | |
| AU2003205174A1 (en) | Molecules for disease detection and treatment | |
| AU2003209265A1 (en) | Mrp9 and its use detecting and treating cancer | |
| AU2002306952A1 (en) | Detection and treatment of colorectal cancer | |
| AU2004281077A1 (en) | Methods and agents for the treatment of cancer | |
| AU2002305138A1 (en) | Methods and materials for cancer treatment | |
| GB0200110D0 (en) | Cancer detection | |
| AU2003231912A1 (en) | Methods of detecting and treating prostate cancer | |
| GB0223325D0 (en) | Treating cancer | |
| GB2383538B (en) | Cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |